Theravance Biopharma (NASDAQ:TBPH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $40.00 price target on the stock.
Theravance Biopharma (NASDAQ:TBPH) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at
Wall St
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at
Wall Stre
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review [Yahoo! Finance]